☰

Jing-Ping Liou, PhD - Publications

Affiliations: 
1990-1994 College of Pharmacy Taipei Medical University 
 1994-2000 College of Pharmacy National Taiwan University, Taipei, Taipei City, Taiwan 
 2000-2004 National Health Research Institutes, Taiwan, Taiwan 
 2004- College of Pharmacy Taipei Medical University 
Area:
Medicinal Chemistry, Drug Discovery, Translational Medicine, Drug Design, Drug Development
Website:
https://tmu.pure.elsevier.com/zh/persons/jing-ping-liou-2
Tree Info Similar researchers PubMed Report error

128 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Sharma R, Chiang YH, Chen HC, Lin HY, Yang WB, Nepali K, Lai MJ, Chen KY, Liou JP, Hsu TI. Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress. Cancer Letters. 216666. PMID 38311053 DOI: 10.1016/j.canlet.2024.216666  0.36
2024 Sharma S, Wang SA, Yang WB, Lin HY, Lai MJ, Chen HC, Kao TY, Hsu FL, Nepali K, Hsu TI, Liou JP. First-in-Class Dual EZH2-HSP90 Inhibitor Eliciting Striking Antiglioblastoma Activity and . Journal of Medicinal Chemistry. PMID 38285511 DOI: 10.1021/acs.jmedchem.3c02053  0.384
2023 Chen TY, Shyur E, Ma TH, Wijeyewickrema L, Lin SW, Kao MR, Liang PH, Shie JJ, Chuang EY, Liou JP, Hsieh YSY. Effect of Sulfotyrosine and Negatively Charged Amino Acid of Leech-Derived Peptides on Binding and Inhibitory Activity Against Thrombin. Chembiochem : a European Journal of Chemical Biology. e202300744. PMID 38055188 DOI: 10.1002/cbic.202300744  0.63
2023 Sharma S, Chandra K, Naik A, Sharma A, Sharma R, Thakur A, Grewal AS, Dhingra AK, Banerjee A, Liou JP, Guru SK, Nepali K. Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancer. Journal of Enzyme Inhibition and Medicinal Chemistry. 38: 2276665. PMID 37919954 DOI: 10.1080/14756366.2023.2276665  0.392
2023 Tsai FL, Huang HL, Lai MJ, Liou JP, Pan SL, Yang CR. Anticancer Study of a Novel Pan-HDAC Inhibitor MPT0G236 in Colorectal Cancer Cells. International Journal of Molecular Sciences. 24. PMID 37628767 DOI: 10.3390/ijms241612588  0.668
2023 Rana M, Thakur A, Kaur C, Pan CH, Lee SB, Liou JP, Nepali K. Prudent tactics to sail the boat of PARP inhibitors as therapeutics for diverse malignancies. Expert Opinion On Drug Discovery. 1-25. PMID 37525475 DOI: 10.1080/17460441.2023.2241818  0.313
2023 Narwanti I, Yu ZY, Sethy B, Lai MJ, Lee HY, Olena P, Lee SB, Liou JP. 6-Regioisomeric 5,8-quinolinediones as potent CDC25 inhibitors against colorectal cancers. European Journal of Medicinal Chemistry. 258: 115505. PMID 37302341 DOI: 10.1016/j.ejmech.2023.115505  0.669
2023 Liu YM, Liou JP. An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 - present). Expert Opinion On Therapeutic Patents. 1-21. PMID 37249104 DOI: 10.1080/13543776.2023.2219393  0.316
2023 Tseng HJ, Banerjee S, Qian B, Lai MJ, Wu TY, Hsu TI, Lin TE, Hsu KC, Chuang KH, Liou JP, Shih JC. Design, synthesis, and biological activity of dual monoamine oxidase A and heat shock protein 90 inhibitors, N-Methylpropargylamine-conjugated 4-isopropylresorcinol for glioblastoma. European Journal of Medicinal Chemistry. 256: 115459. PMID 37172473 DOI: 10.1016/j.ejmech.2023.115459  0.682
2023 Lai MJ, Lee HY, Chuang HY, Chang LH, Tsai AC, Chen MC, Huang HL, Wu YW, Teng CM, Pan SL, Liu YM, Mehndiratta S, Liou JP. Correction to "-Sulfonyl-aminobiaryls as Antitubulin Agents and Inhibitors of Signal Transducers and Activators of Transcription 3 (STAT3) Signaling". Journal of Medicinal Chemistry. PMID 37079573 DOI: 10.1021/acs.jmedchem.3c00574  0.696
2023 Nepali K, Wu AC, Lo WL, Chopra B, Lai MJ, Chuang JY, Liou JP. Rationally designed donepezil-based hydroxamates modulate Sig-1R and HDAC isoforms to exert anti-glioblastoma effects. European Journal of Medicinal Chemistry. 248: 115054. PMID 36630883 DOI: 10.1016/j.ejmech.2022.115054  0.8
2022 Wang YS, Yeh TK, Chang WC, Liou JP, Liu YM, Huang WC. 2,6-Difluorobenzamide derivatives as store-operated calcium channel (SOC) inhibitors. European Journal of Medicinal Chemistry. 243: 114773. PMID 36179401 DOI: 10.1016/j.ejmech.2022.114773  0.333
2022 Li J, Hsiung SY, Kao MR, Xing X, Chang SC, Wang D, Hsieh PY, Liang PH, Zhu Z, Cheng TR, Shie JJ, Liou JP, Abbott DW, Kwon SW, Hsieh YSY. Structural compositions and biological activities of cell wall polysaccharides in the rhizome, stem, and leaf of Polygonatum odoratum (Mill.) Druce. Carbohydrate Research. 521: 108662. PMID 36099721 DOI: 10.1016/j.carres.2022.108662  0.605
2022 Nepali K, Sharma R, Sharma S, Thakur A, Liou JP. Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal. Journal of Biomedical Science. 29: 65. PMID 36064696 DOI: 10.1186/s12929-022-00847-6  0.637
2022 Sharma R, Chatterjee E, Mathew J, Sharma S, Rao NV, Pan CH, Lee SB, Dhingra A, Grewal AS, Liou JP, Guru SK, Nepali K. Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier. European Journal of Medicinal Chemistry. 240: 114602. PMID 35858522 DOI: 10.1016/j.ejmech.2022.114602  0.735
2022 Thakur A, Faujdar C, Sharma R, Sharma S, Malik B, Nepali K, Liou JP. Glioblastoma: Current Status, Emerging Targets, and Recent Advances. Journal of Medicinal Chemistry. 65: 8596-8685. PMID 35786935 DOI: 10.1021/acs.jmedchem.1c01946  0.647
2022 Wu TY, Chen M, Chen IC, Chen YJ, Chen CY, Wang CH, Cheng JJ, Nepali K, Chuang KH, Liou JP. Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment. Journal of Advanced Research. PMID 35752438 DOI: 10.1016/j.jare.2022.06.009  0.653
2022 Sharma R, Sharma S, Thakur A, Singh A, Singh J, Nepali K, Liou JP. The Role of Epigenetic Mechanisms in Autoimmune, Neurodegenerative, Cardiovascular, and Imprinting Disorders. Mini Reviews in Medicinal Chemistry. PMID 35176978 DOI: 10.2174/1389557522666220217103441  0.624
2022 Mehndiratta S, Qian B, Chuang JY, Liou JP, Shih JC. -Methylpropargylamine-Conjugated Hydroxamic Acids as Dual Inhibitors of Monoamine Oxidase A and Histone Deacetylase for Glioma Treatment. Journal of Medicinal Chemistry. PMID 35005974 DOI: 10.1021/acs.jmedchem.1c01726  0.392
2021 Ojha R, Chen IC, Hsieh CM, Nepali K, Lai RW, Hsu KC, Lin TE, Pan SL, Chen MC, Liou JP. Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent. Journal of Medicinal Chemistry. PMID 34908406 DOI: 10.1021/acs.jmedchem.1c00966  0.832
2021 Hsieh TH, Liang ML, Zheng JH, Lin YC, Yang YC, Vo TH, Liou JP, Yen Y, Chen CH. Combining an Autophagy Inhibitor, MPT0L145, with Abemaciclib Is a New Therapeutic Strategy in GBM Treatment. Cancers. 13. PMID 34885226 DOI: 10.3390/cancers13236117  0.324
2021 Wang CA, Li CF, Huang RC, Li YH, Liou JP, Tsai SJ. Suppression of extracellular vesicle VEGF-C-mediated lymphangiogenesis and pancreatic cancer early dissemination by a selective HDAC1/2 inhibitor. Molecular Cancer Therapeutics. PMID 34210825 DOI: 10.1158/1535-7163.MCT-20-0963  0.324
2021 Wu YW, Chao MW, Tu HJ, Chen LC, Hsu KC, Liou JP, Yang CR, Yen SC, HuangFu WC, Pan SL. A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo. Oncogenesis. 10: 39. PMID 33986242 DOI: 10.1038/s41389-021-00331-0  0.325
2021 Liu YM, Tu HJ, Wu CH, Lai MJ, Yu SC, Chao MW, Wu YW, Teng CM, Pan SL, Liou JP. Ring-opening of five-membered heterocycles conjugated 4-isopropylresorcinol scaffold-based benzamides as HSP90 inhibitors suppressing tumor growth in vitro and in vivo. European Journal of Medicinal Chemistry. 219: 113428. PMID 33934008 DOI: 10.1016/j.ejmech.2021.113428  0.702
2021 Nepali K, Liou JP. Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends. Journal of Biomedical Science. 28: 27. PMID 33840388 DOI: 10.1186/s12929-021-00721-x  0.666
2021 Nepali K, Hsu TI, Hsieh CM, Lo WL, Lai MJ, Hsu KC, Lin TE, Chuang JY, Liou JP. Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma. European Journal of Medicinal Chemistry. 217: 113338. PMID 33744690 DOI: 10.1016/j.ejmech.2021.113338  0.796
2021 Chang TY, Nepali K, Chen YY, Yang YSH, Hsu KC, Yen Y, Pan SL, Liou JP, Lee SB. A novel histone deacetylase inhibitor MPT0L184 dysregulates cell-cycle checkpoints and initiates unscheduled mitotic signaling. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 138: 111485. PMID 33740521 DOI: 10.1016/j.biopha.2021.111485  0.721
2021 Singh A, Chang TY, Kaur N, Hsu KC, Yen Y, Lin TE, Lai MJ, Lee SB, Liou JP. CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition. European Journal of Medicinal Chemistry. 215: 113169. PMID 33588178 DOI: 10.1016/j.ejmech.2021.113169  0.69
2021 Mehndiratta S, Chen MC, Chao YH, Lee CH, Liou JP, Lai MJ, Lee HY. Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms. Journal of Enzyme Inhibition and Medicinal Chemistry. 36: 74-84. PMID 33161799 DOI: 10.1080/14756366.2020.1839446  0.696
2020 Buyandelger B, Bar EE, Hung KS, Chen RM, Chiang YH, Liou JP, Huang HM, Wang JY. Histone deacetylase inhibitor MPT0B291 suppresses Glioma Growth and partially through acetylation of p53. International Journal of Biological Sciences. 16: 3184-3199. PMID 33162824 DOI: 10.7150/ijbs.45505  0.319
2020 Chen IC, Sethy B, Liou JP. Recent Update of HDAC Inhibitors in Lymphoma. Frontiers in Cell and Developmental Biology. 8: 576391. PMID 33015069 DOI: 10.3389/fcell.2020.576391  0.341
2020 Sharma S, Singh A, Sharma S, Sharma R, Singh J, Kinarivala N, Nepali K, Liou JP. Tailored Quinolines Demonstrates Flexibility to Exert Antitumor Effects through Varied Mechanisms - A Medicinal Perspective. Anti-Cancer Agents in Medicinal Chemistry. PMID 32900354 DOI: 10.2174/1871520620666200908104303  0.668
2020 Liu YM, HuangFu WC, Huang HL, Wu WC, Chen YL, Yen Y, Huang HL, Nien CY, Lai MJ, Pan SL, Liou JP. Corrigendum to "1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma" [Eur. J. Med. Chem. 140 (2017) 84-91]. European Journal of Medicinal Chemistry. 202: 112633. PMID 32688164 DOI: 10.1016/J.Ejmech.2020.112633  0.765
2020 Wu WC, Liu YM, Liao YH, Hsu KC, Lien ST, Chen IC, Lai MJ, Li YH, Pan SL, Chen MC, Liou JP. Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells. European Journal of Medicinal Chemistry. 203: 112540. PMID 32683166 DOI: 10.1016/J.Ejmech.2020.112540  0.726
2020 Ojha R, Nepali K, Chen CH, Chuang KH, Wu TY, Lin TE, Hsu KC, Chao MW, Lai MJ, Lin MH, Huang HL, Chang CD, Pan SL, Chen MC, Liou JP. Corrigendum to"Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo"[Eur. J. Med. Chem. 190 (2020 Mar 15) 112086]. European Journal of Medicinal Chemistry. 201: 112404. PMID 32526554 DOI: 10.1016/J.Ejmech.2020.112404  0.797
2020 Cheng KJ, Hsieh CM, Nepali K, Liou JP. Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye. Journal of Medicinal Chemistry. PMID 32482069 DOI: 10.1021/Acs.Jmedchem.9B01033  0.639
2020 Fang YC, Chan L, Liou JP, Tu YK, Lai MJ, Chen CI, Vidyanti AN, Lee HY, Hu CJ. HDAC inhibitor protects chronic cerebral hypoperfusion and oxygen-glucose deprivation injuries via H3K14 and H4K5 acetylation-mediated BDNF expression. Journal of Cellular and Molecular Medicine. PMID 32374084 DOI: 10.1111/Jcmm.15358  0.629
2020 Nepali K, Chang TY, Lai MJ, Hsu KC, Yen Y, Lin TE, Lee SB, Liou JP. Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors. European Journal of Medicinal Chemistry. 196: 112291. PMID 32325365 DOI: 10.1016/j.ejmech.2020.112291  0.808
2020 Wu WC, Liu YM, Lin MH, Liao YH, Lai MJ, Chuang HY, Hung TY, Chen CH, Liou JP. Corrigendum to "Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response" [Eur J Med Chem. 192 2020 112158]. European Journal of Medicinal Chemistry. 196: 112329. PMID 32311605 DOI: 10.1016/j.ejmech.2020.112329  0.741
2020 Lin YC, Chen MC, Hsieh TH, Liou JP, Chen CH. CK1δ as a potential therapeutic target to treat bladder cancer. Aging. 12. PMID 32282334 DOI: 10.18632/aging.102966  0.305
2020 Wu WC, Liu YM, Lin MH, Liao YH, Lai MJ, Chuang HY, Hung TY, Chen CH, Liou JP. Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response. European Journal of Medicinal Chemistry. 192: 112158. PMID 32171161 DOI: 10.1016/j.ejmech.2020.112158  0.764
2020 Liu YM, Kuo CN, Liou JP. Anaplastic lymphoma kinase inhibitors: an updated patent review (2014-2018). Expert Opinion On Therapeutic Patents. PMID 32125908 DOI: 10.1080/13543776.2020.1738389  0.354
2020 Ojha R, Nepali K, Chen CH, Chuang KH, Wu TY, Lin TE, Hsu KC, Chao MW, Lai MJ, Lin MH, Huang HL, Chang CD, Pan SL, Chen MC, Liou JP. Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo. European Journal of Medicinal Chemistry. 190: 112086. PMID 32058238 DOI: 10.1016/J.Ejmech.2020.112086  0.833
2019 Wang SW, Lin MH, Hsu FC, Chen MC, Liou JP, Liu YT, Chen SS, Lee HY. Synthesis and biological evaluation of 2-quinolineacrylamides. Bioorganic & Medicinal Chemistry. 115250. PMID 31924504 DOI: 10.1016/j.bmc.2019.115250  0.407
2019 Kaur N, Fang YC, Lee HY, Singh A, Nepali K, Lin MH, Yeh TK, Lai MJ, Chan L, Tu YK, Banerjee S, Hu CJ, Liou JP. Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment. European Journal of Medicinal Chemistry. 187: 111915. PMID 31838329 DOI: 10.1016/j.ejmech.2019.111915  0.72
2019 Mehndiratta S, Lin MH, Wu YW, Chen CH, Wu TY, Chuang KH, Chao MW, Chen YY, Pan SL, Chen MC, Liou JP. N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression. European Journal of Medicinal Chemistry. 185: 111725. PMID 31655430 DOI: 10.1016/j.ejmech.2019.111725  0.429
2019 Chen MC, Lin YC, Liao YH, Liou JP, Chen CH. MPT0G612, a Novel HDAC6 Inhibitor, Induces Apoptosis and Suppresses IFN-γ-Induced Programmed Death-Ligand 1 in Human Colorectal Carcinoma Cells. Cancers. 11. PMID 31652644 DOI: 10.3390/cancers11101617  0.324
2019 Chen CH, Hsieh TH, Lin YC, Liu YR, Liou JP, Yen Y. Targeting Autophagy by MPT0L145, a Highly Potent PIK3C3 Inhibitor, Provides Synergistic Interaction to Targeted or Chemotherapeutic Agents in Cancer Cells. Cancers. 11. PMID 31514441 DOI: 10.3390/cancers11091345  0.341
2019 Nepali K, Lin MH, Chao MW, Peng SJ, Hsu KC, Eight Lin T, Chen MC, Lai MJ, Pan SL, Liou JP. Amide-tethered quinoline-resorcinol conjugates as a new class of HSP90 inhibitors suppressing the growth of prostate cancer cells. Bioorganic Chemistry. 91: 103119. PMID 31349117 DOI: 10.1016/j.bioorg.2019.103119  0.794
2019 Chao MW, Chang LH, Tu HJ, Chang CD, Lai MJ, Chen YY, Liou JP, Teng CM, Pan SL. Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status. Clinical Epigenetics. 11: 85. PMID 31142371 DOI: 10.1186/s13148-019-0681-6  0.6
2019 Hsieh YL, Tu HJ, Pan SL, Liou JP, Yang CR. Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo. Biochimica Et Biophysica Acta. Molecular Cell Research. PMID 30867138 DOI: 10.1016/j.bbamcr.2019.03.003  0.342
2019 Liu YM, Chen CH, Yeh TK, Liou JP. Synthesis and evaluation of novel 7H-pyrrolo-[2,3-d]pyrimidine derivatives as potential anticancer agents. Future Medicinal Chemistry. PMID 30789758 DOI: 10.4155/fmc-2018-0564  0.35
2018 Lai MJ, Ojha R, Lin MH, Liu YM, Lee HY, Lin TE, Hsu KC, Chang CY, Chen MC, Nepali K, Chang JY, Liou JP. 1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase. European Journal of Medicinal Chemistry. 162: 612-630. PMID 30476825 DOI: 10.1016/J.Ejmech.2018.10.066  0.83
2018 Nepali K, Lee HY, Liou JP. Nitro Group Containing Drugs. Journal of Medicinal Chemistry. PMID 30295477 DOI: 10.1021/acs.jmedchem.8b00147  0.624
2018 Lee HY, Fan SJ, Huang FI, Chao HY, Hsu KC, Lin TE, Yeh TK, Lai MJ, Li YH, Huang HL, Yang CR, Liou JP. 5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes. Journal of Medicinal Chemistry. PMID 30028616 DOI: 10.1021/acs.jmedchem.8b00151  0.647
2018 Nepali K, Kumar S, Huang HL, Kuo FC, Lee CH, Kuo CC, Yeh TK, Li YH, Chang JY, Liou JP, Lee HY. Correction: 2-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibition. Organic & Biomolecular Chemistry. PMID 29904758 DOI: 10.1039/c8ob90080a  0.641
2018 Wu YW, Hsu KC, Lee HY, Huang TC, Lin TE, Chen YL, Sung TY, Liou JP, Hwang-Verslues WW, Pan SL, HuangFu WC. A Novel Dual HDAC6 and Tubulin Inhibitor, MPT0B451, Displays Anti-tumor Ability in Human Cancer Cellsand. Frontiers in Pharmacology. 9: 205. PMID 29593536 DOI: 10.3389/fphar.2018.00205  0.422
2018 Ojha R, Huang HL, HuangFu WC, Wu YW, Nepali K, Lai MJ, Su CJ, Sung TY, Chen YL, Pan SL, Liou JP. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC. European Journal of Medicinal Chemistry. 150: 667-677. PMID 29567459 DOI: 10.1016/J.Ejmech.2018.03.006  0.832
2018 Lee HY, Nepali K, Huang FI, Chang CY, Lai MJ, Li YH, Huang HL, Yang CR, Liou JP. (N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in vitro and in Vivo. Journal of Medicinal Chemistry. PMID 29304284 DOI: 10.1021/acs.jmedchem.7b01404  0.818
2017 Chen CH, Changou C, Hsieh TH, Lee YC, Chu CY, Hsu KC, Wang HC, Lin YC, Lo YN, Liu YR, Liou JP, Yen Y. Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29222162 DOI: 10.1158/1078-0432.CCR-17-2066  0.332
2017 Wu TY, Cho TY, Lu CK, Liou JP, Chen MC. Identification of 7-(4'-Cyanophenyl)indoline-1-benzenesulfonamide as a mitotic inhibitor to induce apoptotic cell death and inhibit autophagy in human colorectal cancer cells. Scientific Reports. 7: 12406. PMID 28963527 DOI: 10.1038/s41598-017-12795-5  0.318
2017 Liu YM, HuangFu WC, Huang HL, Wu WC, Chen YL, Yen Y, Huang HL, Nien CY, Lai MJ, Pan SL, Liou JP. 1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma. European Journal of Medicinal Chemistry. 140: 84-91. PMID 28923389 DOI: 10.1016/j.ejmech.2017.09.011  0.791
2017 Mehndiratta S, Wang RS, Huang HL, Su CJ, Hsu CM, Wu YW, Pan SL, Liou JP. 4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo. European Journal of Medicinal Chemistry. 134: 13-23. PMID 28395150 DOI: 10.1016/j.ejmech.2017.03.079  0.472
2017 Yeh YY, Liou JP, Lee YL, Lin JY, Huang HM. MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells. Investigational New Drugs. PMID 28349229 DOI: 10.1007/s10637-017-0457-9  0.303
2017 Chao MW, Huang HL, HuangFu WC, Hsu KC, Liu YM, Wu YW, Lin CF, Chen YL, Lai MJ, Lee HY, Liou JP, Teng CM, Yang CR. An oral quinoline derivative, MPT0B392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cells. Oncotarget. PMID 28186963 DOI: 10.18632/oncotarget.15115  0.63
2017 HuangFu WC, Chao MW, Cheng CC, Wei YC, Wu YW, Liou JP, Hsiao G, Lee YC, Yang CR. Anti-leukemia effects of the novel synthetic 1-benzylindole derivative 21-900 in vitro and in vivo. Scientific Reports. 7: 42291. PMID 28181578 DOI: 10.1038/srep42291  0.334
2017 Liu YM, Nepali K, Liou JP. Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets. Journal of Medicinal Chemistry. 60: 527-553. PMID 28122457 DOI: 10.1021/acs.jmedchem.6b00935  0.62
2016 Nepali K, Lee HY, Lai MJ, Ojha R, Wu TY, Wu GX, Chen MC, Liou JP. Ring-opened tetrahydro-γ-carbolines display cytotoxicity and selectivity with histone deacetylase isoforms. European Journal of Medicinal Chemistry. 127: 115-127. PMID 28038324 DOI: 10.1016/J.Ejmech.2016.12.039  0.83
2016 Lee HY, Lee JF, Kumar S, Wu YW, HuangFu WC, Lai MJ, Li YH, Huang HL, Kuo FC, Hsiao CJ, Cheng CC, Yang CR, Liou JP. 3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity. European Journal of Medicinal Chemistry. 125: 1268-1278. PMID 27886544 DOI: 10.1016/J.Ejmech.2016.11.033  0.743
2016 Huang HL, Chao MW, Li YC, Chang LH, Chen CH, Chen MC, Cheng CC, Liou JP, Teng CM, Pan SL. MPT0G066, a novel anti-mitotic drug, induces JNK-independent mitotic arrest, JNK-mediated apoptosis, and potentiates antineoplastic effect of cisplatin in ovarian cancer. Scientific Reports. 6: 31664. PMID 27526962 DOI: 10.1038/srep31664  0.35
2016 Peng HY, Cheng YC, Hsu YM, Wu GH, Kuo CC, Liou JP, Chang JY, Jin SC, Shiah SG. MPT0B098, a Microtubule Inhibitor, Suppresses JAK2/STAT3 Signaling Pathway through Modulation of SOCS3 Stability in Oral Squamous Cell Carcinoma. Plos One. 11: e0158440. PMID 27367272 DOI: 10.1371/journal.pone.0158440  0.325
2016 Lee HY, Chang CY, Su CJ, Huang HL, Mehndiratta S, Chao YH, Hsu CM, Kumar S, Sung TY, Huang YZ, Li YH, Yang CR, Liou JP. 2-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase. European Journal of Medicinal Chemistry. 122: 92-101. PMID 27344487 DOI: 10.1016/j.ejmech.2016.06.023  0.323
2016 Nepali K, Ojha R, Lee HY, Liou JP. Early investigational tubulin inhibitors as novel cancer therapeutics. Expert Opinion On Investigational Drugs. PMID 27186892 DOI: 10.1080/13543784.2016.1189901  0.8
2016 Chen CH, Liu YM, Pan SL, Liu YR, Liou JP, Yen Y. Trichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivo. Oncotarget. PMID 27029060 DOI: 10.18632/oncotarget.8380  0.426
2015 Nepali K, Kumar S, Huang HL, Kuo FC, Lee CH, Kuo CC, Yeh TK, Li YH, Chang JY, Liou JP, Lee HY. 2-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibition. Organic & Biomolecular Chemistry. 14: 716-23. PMID 26694589 DOI: 10.1039/c5ob02100f  0.742
2015 Chen MC, Huang HH, Lai CY, Lin YJ, Liou JP, Lai MJ, Li YH, Teng CM, Yang CR. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma. Oncotarget. PMID 26587975 DOI: 10.18632/Oncotarget.6352  0.668
2015 Chen CH, Lee CH, Liou JP, Teng CM, Pan SL. Molecular mechanisms underlying the antitumor activity of (E)-N-hydroxy-3-(1-(4-methoxyphenylsulfonyl)-1,2,3,4-tetrahydroquinolin-6-yl)acrylamide in human colorectal cancer cells in vitro and in vivo. Oncotarget. PMID 26462017  0.443
2015 Mehndiratta S, Pan SL, Kumar S, Liou JP. Indole-3-ethylsulfamoylphenylacrylamides with Potent Anti-proliferative and Anti-angiogenic Activities. Anti-Cancer Agents in Medicinal Chemistry. PMID 26459769  0.424
2015 Liu YM, Lee HY, Lai MJ, Pan SL, Huang HL, Kuo FC, Chen MC, Liou JP. Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells. Organic & Biomolecular Chemistry. PMID 26309122 DOI: 10.1039/C5Ob01509J  0.724
2015 Lai MJ, Lee HY, Chuang HY, Chang LH, Tsai AC, Chen MC, Huang HL, Wu YW, Teng CM, Pan SL, Liu YM, Mehndiratta S, Liou JP. N-Sulfonyl-aminobiaryls as Antitubulin Agents and Inhibitors of Signal Transducer and Activator of Transcription 3 (STAT3) Signaling. Journal of Medicinal Chemistry. PMID 26241032 DOI: 10.1021/Acs.Jmedchem.5B00659  0.783
2015 Lee HY, Chang CY, Lai MJ, Chuang HY, Kuo CC, Chang CY, Chang JY, Liou JP. Antimitotic and antivascular activity of heteroaroyl-2-hydroxy-3,4,5-trimethoxybenzenes. Bioorganic & Medicinal Chemistry. 23: 4230-6. PMID 26160020 DOI: 10.1016/j.bmc.2015.06.043  0.78
2015 Chao MW, Lai MJ, Liou JP, Chang YL, Wang JC, Pan SL, Teng CM. The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo. Journal of Hematology & Oncology. 8: 82. PMID 26156322 DOI: 10.1186/S13045-015-0176-7  0.621
2015 Huang YC, Huang FI, Mehndiratta S, Lai SC, Liou JP, Yang CR. Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis. Oncotarget. PMID 26087180  0.415
2015 Pai HC, Kumar S, Shen CC, Liou JP, Pan SL, Teng CM. MT-4 suppresses resistant ovarian cancer growth through targeting tubulin and HSP27. Plos One. 10: e0123819. PMID 25874627 DOI: 10.1371/journal.pone.0123819  0.339
2015 Huang HL, Peng CY, Lai MJ, Chen CH, Lee HY, Wang JC, Liou JP, Pan SL, Teng CM. Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo. Oncotarget. 6: 4976-91. PMID 25669976 DOI: 10.18632/Oncotarget.3213  0.686
2015 Liu YM, Lee HY, Chen CH, Lee CH, Wang LT, Pan SL, Lai MJ, Yeh TK, Liou JP. 1-Arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells. European Journal of Medicinal Chemistry. 89: 320-30. PMID 25462248 DOI: 10.1016/J.Ejmech.2014.10.052  0.674
2014 Lee HY, Wang LT, Li YH, Pan SL, Chen YL, Teng CM, Liou JP. Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases. Organic & Biomolecular Chemistry. 12: 8966-76. PMID 25277250 DOI: 10.1039/c4ob00542b  0.381
2014 Wang CY, Liou JP, Tsai AC, Lai MJ, Liu YM, Lee HY, Wang JC, Pan SL, Teng CM. A novel action mechanism for MPT0G013, a derivative of arylsulfonamide, inhibits tumor angiogenesis through up-regulation of TIMP3 expression. Oncotarget. 5: 9838-50. PMID 25226613 DOI: 10.18632/Oncotarget.2451  0.635
2014 Mehndiratta S, Hsieh YL, Liu YM, Wang AW, Lee HY, Liang LY, Kumar S, Teng CM, Yang CR, Liou JP. Indole-3-ethylsulfamoylphenylacrylamides: potent histone deacetylase inhibitors with anti-inflammatory activity. European Journal of Medicinal Chemistry. 85: 468-79. PMID 25113875 DOI: 10.1016/j.ejmech.2014.08.020  0.369
2014 Mehndiratta S, Chiang YF, Lai MJ, Lee HY, Chen MC, Kuo CC, Chang CY, Chang JY, Liou JP. Concise syntheses of 7-anilino-indoline-N-benzenesulfonamides as antimitotic and vascular disrupting agents. Bioorganic & Medicinal Chemistry. 22: 4917-23. PMID 25059503 DOI: 10.1016/J.Bmc.2014.06.042  0.713
2014 Wang LT, Liou JP, Li YH, Liu YM, Pan SL, Teng CM. A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKCδ and E-cadherin. Oncotarget. 5: 5651-62. PMID 25015091  0.371
2014 Lee HY, Tsai AC, Chen MC, Shen PJ, Cheng YC, Kuo CC, Pan SL, Liu YM, Liu JF, Yeh TK, Wang JC, Chang CY, Chang JY, Liou JP. Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells. Journal of Medicinal Chemistry. 57: 4009-22. PMID 24766560 DOI: 10.1021/jm401899x  0.459
2014 Hsieh IN, Liou JP, Lee HY, Lai MJ, Li YH, Yang CR. Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009. Cell Death & Disease. 5: e1166. PMID 24722291 DOI: 10.1038/Cddis.2014.133  0.636
2014 Tsai AC, Wang CY, Liou JP, Pai HC, Hsiao CJ, Chang JY, Wang JC, Teng CM, Pan SL. Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib. Cell Death & Disease. 5: e1162. PMID 24722287 DOI: 10.1038/cddis.2014.128  0.391
2014 Chang CY, Chuang HY, Lee HY, Yeh TK, Kuo CC, Chang CY, Chang JY, Liou JP. Antimitotic and vascular disrupting agents: 2-hydroxy-3,4,5-trimethoxybenzophenones. European Journal of Medicinal Chemistry. 77: 306-14. PMID 24657567 DOI: 10.1016/j.ejmech.2014.02.061  0.644
2014 Chen CH, Chen MC, Wang JC, Tsai AC, Chen CS, Liou JP, Pan SL, Teng CM. Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1274-87. PMID 24520095 DOI: 10.1158/1078-0432.CCR-12-3909  0.331
2014 Liu YM, Chen HL, Lee HY, Liou JP. Tubulin inhibitors: a patent review. Expert Opinion On Therapeutic Patents. 24: 69-88. PMID 24313741 DOI: 10.1517/13543776.2014.859247  0.3
2013 Lee HY, Pan SL, Su MC, Liu YM, Kuo CC, Chang YT, Wu JS, Nien CY, Mehndiratta S, Chang CY, Wu SY, Lai MJ, Chang JY, Liou JP. Furanylazaindoles: potent anticancer agents in vitro and in vivo. Journal of Medicinal Chemistry. 56: 8008-18. PMID 24106982 DOI: 10.1021/jm4011115  0.822
2013 Chen MC, Chen CH, Wang JC, Tsai AC, Liou JP, Pan SL, Teng CM. The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells. Cell Death & Disease. 4: e810. PMID 24052078 DOI: 10.1038/cddis.2013.330  0.333
2013 Lee WH, Liu HE, Chang JY, Liou JP, Huang HM. MPT0B169, a new tubulin inhibitor, inhibits cell growth and induces G2/M arrest in nonresistant and paclitaxel-resistant cancer cells. Pharmacology. 92: 90-8. PMID 23949011 DOI: 10.1159/000351852  0.358
2013 Lee HY, Yang CR, Lai MJ, Huang HL, Hsieh YL, Liu YM, Yeh TK, Li YH, Mehndiratta S, Teng CM, Liou JP. 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines histone deacetylase inhibitors are potent cytokine release suppressors. Chembiochem : a European Journal of Chemical Biology. 14: 1248-54. PMID 23788254 DOI: 10.1002/Cbic.201300201  0.655
2013 Cheng YC, Liou JP, Kuo CC, Lai WY, Shih KH, Chang CY, Pan WY, Tseng JT, Chang JY. MPT0B098, a novel microtubule inhibitor that destabilizes the hypoxia-inducible factor-1α mRNA through decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR. Molecular Cancer Therapeutics. 12: 1202-12. PMID 23619299 DOI: 10.1158/1535-7163.MCT-12-0778  0.328
2013 Chiang NJ, Lin CI, Liou JP, Kuo CC, Chang CY, Chen LT, Chang JY. A novel synthetic microtubule inhibitor, MPT0B214 exhibits antitumor activity in human tumor cells through mitochondria-dependent intrinsic pathway. Plos One. 8: e58953. PMID 23554962 DOI: 10.1371/journal.pone.0058953  0.404
2013 Lee HY, Yang CR, Lai MJ, Huang HL, Hsieh YL, Liu YM, Yeh TK, Li YH, Mehndiratta S, Teng CM, Liou JP. Inside Cover: 1-Arylsulfonyl-5-(N-hydroxyacrylamide)indolines Histone Deacetylase Inhibitors Are Potent Cytokine Release Suppressors (ChemBioChem 10/2013) Chembiochem. 14: 1150-1150. DOI: 10.1002/Cbic.201390034  0.61
2012 Lee HY, Lee LW, Nien CY, Kuo CC, Lin PY, Chang CY, Chang JY, Liou JP. Application of Suzuki arylation, Sonogashira ethynylation and Rosenmund-von Braun cyanation in the exploration of substitution effects on the anticancer activity of 2-aroylquinolines. Organic & Biomolecular Chemistry. 10: 9593-600. PMID 23132325 DOI: 10.1039/c2ob26614h  0.768
2012 Huang HL, Huang HL, Lee HY, Tsai AC, Peng CY, Lai MJ, Wang JC, Pan SL, Teng CM, Liou JP. Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivo. Plos One. 7: e43645. PMID 22928010 DOI: 10.1371/Journal.Pone.0043645  0.706
2012 Lai MJ, Huang HL, Pan SL, Liu YM, Peng CY, Lee HY, Yeh TK, Huang PH, Teng CM, Chen CS, Chuang HY, Liou JP. Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo. Journal of Medicinal Chemistry. 55: 3777-91. PMID 22439863 DOI: 10.1021/jm300197a  0.8
2011 Lee HY, Chang JY, Nien CY, Kuo CC, Shih KH, Wu CH, Chang CY, Lai WY, Liou JP. 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. Part 2. The impact of bridging groups at position C-2. Journal of Medicinal Chemistry. 54: 8517-25. PMID 22060033 DOI: 10.1021/jm201031f  0.818
2011 Lai MJ, Chang JY, Lee HY, Kuo CC, Lin MH, Hsieh HP, Chang CY, Wu JS, Wu SY, Shey KS, Liou JP. Synthesis and biological evaluation of 1-(4'-Indolyl and 6'-Quinolinyl) indoles as a new class of potent anticancer agents. European Journal of Medicinal Chemistry. 46: 3623-9. PMID 21641700 DOI: 10.1016/J.Ejmech.2011.04.065  0.694
2011 Lee HY, Chang JY, Chang LY, Lai WY, Lai MJ, Shih KH, Kuo CC, Chang CY, Liou JP. Concise syntheses of N-aryl-5,6,7-trimethoxyindoles as antimitotic and vascular disrupting agents: application of the copper-mediated Ullmann-type arylation. Organic & Biomolecular Chemistry. 9: 3154-7. PMID 21416070 DOI: 10.1039/C0Ob01038C  0.624
2011 Hsieh CC, Lee HY, Nien CY, Kuo CC, Chang CY, Chang JY, Liou JP. Synthesis and biological evaluation of 4-aroyl-6,7,8-trimethoxyquinolines as a novel class of anticancer agents. Molecules (Basel, Switzerland). 16: 2274-84. PMID 21383664 DOI: 10.3390/molecules16032274  0.813
2011 Chuang HY, Chang JY, Lai MJ, Kuo CC, Lee HY, Hsieh HP, Chen YJ, Chen LT, Pan WY, Liou JP. 2-amino-3,4,5-trimethoxybenzophenones as potent tubulin polymerization inhibitors. Chemmedchem. 6: 450-6. PMID 21360819 DOI: 10.1002/cmdc.201000479  0.789
2010 Nien CY, Chen YC, Kuo CC, Hsieh HP, Chang CY, Wu JS, Wu SY, Liou JP, Chang JY. 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. Journal of Medicinal Chemistry. 53: 2309-13. PMID 20148562 DOI: 10.1021/jm900685y  0.824
2010 Chang JY, Lai MJ, Chang YT, Lee HY, Cheng YC, Kuo CC, Su MC, Chang CY, Liou JP. Synthesis and biological evaluation of 7-arylindoline-1-benzenesulfonamides as a novel class of potent anticancer agents Medchemcomm. 1: 152-155. DOI: 10.1039/c0md00052c  0.415
2009 Wu YS, Coumar MS, Chang JY, Sun HY, Kuo FM, Kuo CC, Chen YJ, Chang CY, Hsiao CL, Liou JP, Chen CP, Yao HT, Chiang YK, Tan UK, Chen CT, et al. Synthesis and evaluation of 3-aroylindoles as anticancer agents: metabolite approach. Journal of Medicinal Chemistry. 52: 4941-5. PMID 19586033 DOI: 10.1021/jm900060s  0.313
2009 Lai MJ, Kuo CC, Yeh TK, Hsieh HP, Chen LT, Pan WY, Hsu KY, Chang JY, Liou JP. Synthesis and structure-activity relationships of 1-benzyl-4,5,6-trimethoxyindoles as a novel class of potent antimitotic agents. Chemmedchem. 4: 588-93. PMID 19266513 DOI: 10.1002/cmdc.200800405  0.674
2008 Reddy GR, Kuo CC, Tan UK, Coumar MS, Chang CY, Chiang YK, Lai MJ, Yeh JY, Wu SY, Chang JY, Liou JP, Hsieh HP. Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents. Journal of Medicinal Chemistry. 51: 8163-7. PMID 19053773 DOI: 10.1021/Jm8008635  0.694
2008 Liou JP, Wu ZY, Kuo CC, Chang CY, Lu PY, Chen CM, Hsieh HP, Chang JY. Discovery of 4-amino and 4-hydroxy-1-aroylindoles as potent tubulin polymerization inhibitors. Journal of Medicinal Chemistry. 51: 4351-5. PMID 18588280 DOI: 10.1021/jm800150d  0.396
2007 Liou JP, Wu CY, Hsieh HP, Chang CY, Chen CM, Kuo CC, Chang JY. 4- and 5-aroylindoles as novel classes of potent antitubulin agents. Journal of Medicinal Chemistry. 50: 4548-52. PMID 17685504 DOI: 10.1021/jm070557q  0.439
2007 Liou JP, Hsu KS, Kuo CC, Chang CY, Chang JY. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule. The Journal of Pharmacology and Experimental Therapeutics. 323: 398-405. PMID 17660383 DOI: 10.1124/jpet.107.126680  0.383
2006 Chang JY, Hsieh HP, Chang CY, Hsu KS, Chiang YF, Chen CM, Kuo CC, Liou JP. 7-Aroyl-aminoindoline-1-sulfonamides as a novel class of potent antitubulin agents. Journal of Medicinal Chemistry. 49: 6656-9. PMID 17154496 DOI: 10.1021/jm061076u  0.445
2006 Chang JY, Yang MF, Chang CY, Chen CM, Kuo CC, Liou JP. 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. Journal of Medicinal Chemistry. 49: 6412-5. PMID 17034147 DOI: 10.1021/jm060616k  0.423
2006 Liou JP, Mahindroo N, Chang CW, Guo FM, Lee SW, Tan UK, Yeh TK, Kuo CC, Chang YW, Lu PH, Tung YS, Lin KT, Chang JY, Hsieh HP. Structure-activity relationship studies of 3-aroylindoles as potent antimitotic agents. Chemmedchem. 1: 1106-18. PMID 16952120 DOI: 10.1002/cmdc.200600125  0.336
2004 Liou JP, Chang YL, Kuo FM, Chang CW, Tseng HY, Wang CC, Yang YN, Chang JY, Lee SJ, Hsieh HP. Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents Journal of Medicinal Chemistry. 47: 4247-4257. PMID 15293996 DOI: 10.1021/jm049802l  0.407
2004 Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT, Chang JY. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Research. 64: 4621-8. PMID 15231674 DOI: 10.1158/0008-5472.CAN-03-3474  0.392
2004 Liou JP, Chang JY, Chang CW, Chang CY, Mahindroo N, Kuo FM, Hsieh HP. Synthesis and structure-activity relationships of 3-aminobenzophenones as antimitotic agents Journal of Medicinal Chemistry. 47: 2897-2905. PMID 15139768 DOI: 10.1021/jm0305974  0.324
2003 Chang JY, Hsieh HP, Pan WY, Liou JP, Bey SJ, Chen LT, Liu JF, Song JS. Dual inhibition of topoisomerase I and tubulin polymerization by BPR0Y007, a novel cytotoxic agent Biochemical Pharmacology. 65: 2009-2019. PMID 12787881 DOI: 10.1016/S0006-2952(03)00197-7  0.316
2002 Liou JP, Chang CW, Song JS, Yang YN, Yeh CF, Tseng HY, Lo YK, Chang YL, Chang CM, Hsieh HP. Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents. Journal of Medicinal Chemistry. 45: 2556-62. PMID 12036364 DOI: 10.1021/JM010365+  0.456
Show low-probability matches.